Healthcare / Medical DevicesStockholm
$33.80
-0.10 (-0.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $23.4M · quality 56.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
38.4x
↑EV/EBITDA
36.1x
↑ROE
3.0%
↑Gross Margin
71.5%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.6%
FCF CAGR
—
FCF margin
11.4%
FCF / Net income
4.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $441.9M · net income $10.5M · FCF $50.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $441.9M | $441.9M | $469.0M | $424.6M | $301.3M |
| Net Income | $10.5M | $10.5M | $56.4M | $35.5M | $7.5M |
| EBITDA | $27.1M | $27.1M | $89.9M | $53.2M | $32.0M |
| EPS | 0.31 | 0.31 | 1.67 | 1.05 | 0.22 |
| Gross Margin | 71.5% | 71.5% | 68.9% | 67.6% | 68.1% |
| Operating Margin | 13.7% | 13.7% | 15.0% | 11.7% | 7.2% |
| Net Margin | 2.4% | 2.4% | 12.0% | 8.4% | 2.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.03 | 0.01 | 0.02 |
| Current Ratio | 3.10 | 3.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $50.3M | $50.3M | $23.4M | $16.5M | $-1.5M |
| Returns | |||||
| ROE | 3.0% | 3.0% | 17.4% | 13.1% | 3.1% |
| Valuation | |||||
| P/E | 38.41 | 38.41 | 17.63 | 39.86 | 179.09 |
| EV/EBITDA | 36.14 | 36.14 | 9.48 | 24.18 | 37.87 |
| P/B | 3.29 | 3.29 | 3.06 | 5.21 | 5.48 |
| Growth & Yield | |||||
| Revenue Growth | -5.8% | -5.8% | 10.5% | 40.9% | — |
| EPS Growth | -81.4% | -81.4% | 59.0% | 377.3% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
113.1%
EPS terminal req.
$3.00
Spread vs growth
-194.5%
5Y implied EPS CAGR
63.6%
EPS terminal req.
$3.63
Spread vs growth
-145.0%
10Y implied EPS CAGR
34.1%
EPS terminal req.
$5.84
Spread vs growth
-115.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.2%
Start / end P/E
19.8x → 110.6x
EPS bridge
1.67 → 0.31
Residual
-374.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.